Incidence, clinical features, and risk factors of fluoroquinolone-induced acute liver injury: a case-control study
Autor: | Hong-Yi Yang, Wangping Jia, Dai-Hong Guo, Yuanjie Xu, Xiao-Yu Wang, Man Zhu |
---|---|
Rok vydání: | 2019 |
Předmět: |
Liver injury
medicine.medical_specialty Chemical Health and Safety business.industry Incidence (epidemiology) Case-control study Alcohol abuse General Medicine 030204 cardiovascular system & hematology medicine.disease Logistic regression Chinese people 03 medical and health sciences 0302 clinical medicine Internal medicine Pharmacovigilance medicine Pharmacology (medical) 030212 general & internal medicine General Pharmacology Toxicology and Pharmaceutics Adverse effect business Safety Research |
Zdroj: | Therapeutics and Clinical Risk Management. 15:389-395 |
ISSN: | 1178-203X |
DOI: | 10.2147/tcrm.s195802 |
Popis: | Background Fluoroquinolone-related hepatotoxicity is rare but serious and is attracting increasing attention. We explored the incidence, clinical features and risk factors of acute liver injury associated with fluoroquinolone use. Materials and methods Based on the Adverse Drug Events Active Surveillance and Assessment System that we developed, we carried out a case-control study by enrolling patients who were hospitalized and received fluoroquinolones to treat or prevent infections at the Chinese People's Liberation Army General Hospital from Jan 2016 to Dec 2017. The incidence of fluoroquinolone-induced acute liver injury was estimated, and logistic regression was used to reveal the risk factors of this adverse reaction. Results We found that 17,822 patients received fluoroquinolones, and 13,678 of them met the inclusion criteria. A total of 91 patients developed acute liver injury after receiving the medication, and 369 controls were matched to these patients. The overall incidence of fluoroquinolone-induced acute liver injury in the Chinese population is approximately 6-7 cases per 1,000 individuals annually. Multivariate logistic regression analysis showed that older age slightly decreased the risk of hepatotoxicity (OR, 0.98; 95% CI, 0.96-0.99). The male sex (OR, 2.19; 95% CI, 1.07-4.48), alcohol abuse (OR, 2.91; 95% CI, 1.39-6.11) and hepatitis B carrier status (OR, 2.38; 95% CI, 1.04-5.48) increased the risk of liver injury. Concurrent use of cephalosporins or carbapenems was also associated with an increased risk. Conclusion Increased risk of fluoroquinolone-related hepatotoxicity may be associated with youth, the male sex, alcohol abuse, hepatitis B carrier status and the concurrent use of cephalosporins or carbapenems. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |